Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Placebo-controlled Study to Determine the Efficacy and Safety of 300 and 450 µg/Day Transdermal Testosterone in Female Patients With Low Ejection Fraction and Symptomatic Heart Failure.

Next Previous
Trial Profile

A Placebo-controlled Study to Determine the Efficacy and Safety of 300 and 450 µg/Day Transdermal Testosterone in Female Patients With Low Ejection Fraction and Symptomatic Heart Failure.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Testosterone (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Acronyms CORDELIA
  • Sponsors Procter & Gamble; Warner Chilcott

Most Recent Events

  • 26 May 2010 Actual patient number (17) added as reported by ClinicalTrials.gov.
  • 26 May 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
  • 26 May 2010 Planned end date changed from 1 Dec 2010 to 1 May 2010 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top